Intravenous Amiodarone: Indications for Discontinuation and Transition in Adult Supraventricular Tachycardia

Immediate Criteria for Stopping the Infusion

• Stop the IV infusion immediately if the patient develops hypotension; this adverse effect occurs in ≈ 16 % of adults receiving IV amiodarone【1】.
• Stop or reduce the infusion if bradycardia or any degree of heart block appears; these events are reported in ≈ 4.9 % of treated patients【1】.
• IV amiodarone is contraindicated in patients who develop second‑ or third‑degree AV block and do not have a pacemaker【1】.

Standard IV Infusion Regimen (Adults)

• Loading dose: 150 mg administered intravenously over 10 minutes【2】.
• Maintenance infusion: 1 mg/min for the first 6 hours, then 0.5 mg/min for the subsequent 18 hours【2】.

Transition from IV to Oral Therapy

• When the arrhythmia is controlled (typically within 30 minutes of the anti‑arrhythmic effect), plan a switch to oral therapy【2】【3】.
• Oral dosing based on duration of IV therapy:
  
  • IV < 1 week → 800–1,600 mg oral amiodarone daily【2】.
  • IV 1–3 weeks → 600–800 mg oral daily【2】.
  • IV > 3 weeks → 400 mg oral daily【2】.

Role of Amiodarone in Supraventricular Tachycardia (SVT)

• IV amiodarone should be reserved for cases where first‑line agents (adenosine, vagal maneuvers, calcium‑channel blockers, β‑blockers) are ineffective or contraindicated; it is not a first‑line therapy for SVT【4】【5】【6】.
• In hemodynamically stable SVT that fails other treatments, IV amiodarone is considered a last‑line option【4】【5】【6】.
• The 2019 ESC guidelines downgraded amiodarone’s recommendation for acute management of narrow‑QRS tachycardias【8】.

First‑Line Therapies for SVT (Reference)

• Adenosine, vagal maneuvers, calcium‑channel blockers, and β‑blockers are recommended as initial treatments for SVT【7】【4】【6】.

Monitoring During IV Infusion

• Continuous ECG monitoring to detect bradyarrhythmias or AV block【1】.
• Frequent heart‑rate checks, especially during the first week of therapy【1】.
• Continuous blood‑pressure monitoring to identify hypotension promptly【1】.

Safety and Administration Considerations

• Do not use amiodarone concentrations > 2 mg/mL without a central venous catheter, owing to the risk of phlebitis【1】.
• Short‑duration IV therapy does not produce the long‑term toxicities associated with chronic oral amiodarone use【5】.

Recommendations for Long‑Term Management After IV Therapy

• For chronic rhythm control, prefer oral agents such as verapamil, diltiazem, or β‑blockers rather than oral amiodarone, given the latter’s long‑term toxicity profile【1】【3】【9】.
• Consider definitive catheter ablation (first‑line for AV nodal re‑entrant tachycardia and AV re‑entrant tachycardia) when pharmacologic therapy is insufficient【4】【5】.